Roche Holding AG
Active …ROP.SW
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis …
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. Roche Holding AG has a collaboration agreement with Excalipoint Therapeutics to evaluate EXP011 in DLL3-expressing solid tumors. The company was founded in 1896 and is based in Basel, Switzerland.
288.75B CHF
Healthcare
Drug Manufacturers - General
Switzerland
CHF
Common Stock
- Open
- —
- High
- —
- Low
- —
- Close / last
- —
- Volume
- —
- Prev close
- —
- Change
- —
- Change %
- —
- Session date
- —
- Quote time
- —
Wall Street Target
$370.31
PE Ratio (TTM)
23.64
Forward PE
18.02
Earnings per Share
$15.33
Dividend per Share
$9.80
Market Cap
288.75B
EBITDA
23.96B
Profit Margin
0.1960%
Dividend Yield
0.03%
Price / Sales (TTM)
4.710x
EPS Estimate (Current)
20.351
EPS Estimate (Next Year)
21.903
EV / Revenue
5.010x
EV / EBITDA
14.980x
Revenue Growth (YoY)
-0.012%
Earnings Growth (YoY)
-0.077%
Address
Grenzacherstrasse 124
Basel
4070
Switzerland
Phone
41 61 688 88 80Website
https://www.roche.comEmployees
103249
Dr. Alan Hippe
Chief Financial Officer
Born 1967
Dr. Bruno Eschli
Head of Investor Relations
Dr. Nicolas Dunant
Head of Group Media Relations
Dr. Nina Schwab-Hautzinger
Head of Group Communications
Born 1975
Dr. Severin Schwan Ph.D.
Executive Chairman
Born 1967
Dr. Thomas Schinecker
Group Chief Executive Officer
Born 1975
Mr. Boris L. Zaitra
Head of Corporate Business Development
Born 1972
Ms. Claudia Bockstiegel
General Counsel
Born 1964
Ms. Maria Cristina A. Wilbur
Chief People Officer
Born 1967
Ms. Wafaa Mamilli
Chief Digital & Technology Officer
Born 1967
2026-07-23
Recent quarters & estimate trends
View full earnings (8)| Period | EPS Act. | EPS Est. | Surprise |
|---|---|---|---|
| Dec 2026 | — | — | — |
| Jun 2026 | — | — | — |
| Jun 2021 | 3.49 | 10.24 | -65.92% |
| Jun 2016 | 2.89 | 7.54 | -61.67% |
| Dec 2010 | 2.04 | 6.12 | -66.67% |
| Sep 2010 | 2.04 | — | — |
| Jun 2010 | 6.59 | 6.89 | -4.35% |
| Sep 2008 | 2.08 | 0.81 | 156.79% |
Estimate trends
Dec 2027
21.90 EPS est.
8.0% growth
Dec 2026
20.35 EPS est.
5.0% growth
Sep 2026
—
Jun 2026
—